Semustine

Semustine
Clinical data
ATC code	L01AD03 (WHO) ;
Identifiers
	IUPAC name N-(2-Chloroethyl)-N'-(4-methylcyclohexyl)-N-nitrosourea;
CAS Number	13909-09-6 ;
PubChem CID	5198;
ChemSpider	5009 ;
UNII	6YY7T1T567;
KEGG	D05822 ;
ChEBI	CHEBI:6863 ;
CompTox Dashboard (EPA)	DTXSID8031603 ;
ECHA InfoCard	100.162.271
Chemical and physical data
Formula	C10H18ClN3O2
Molar mass	247.72 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1CCC(CC1)NC(=O)N(CCCl)N=O;
	InChI InChI=1S/C10H18ClN3O2/c1-8-2-4-9(5-3-8)12-10(15)14(13-16)7-6-11/h8-9H,2-7H2,1H3,(H,12,15) ; Key:FVLVBPDQNARYJU-UHFFFAOYSA-N ;
	(what is this?) (verify)

Semustine is a drug used in chemotherapy.^[1] It is structurally similar to lomustine, being distinguished from it only by an additional methyl group. It has been taken off the drug market for investigation of its cancerous effects, rated as IARC Group 1 carcinogen or a known carcinogen.^[2]

References

^ Gastrointestinal Tumor Study Group (April 1992). "Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group". Journal of Clinical Oncology. 10 (4): 549–57. doi:10.1200/jco.1992.10.4.549. PMID 1548520.
^ "Known and Probable Human Carcinogens". American Cancer Society.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Gastrointestinal Tumor Study Group (April 1992). "Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group". Journal of Clinical Oncology. 10 (4): 549–57. doi:10.1200/jco.1992.10.4.549. PMID 1548520.

[2] "Known and Probable Human Carcinogens". American Cancer Society.

[1]

[2]